This document provides Answers to commonly asked Questions about the proof-of-concept (PoC) pilot on the submission and analysis of ‘raw data’ from clinical studies as part of selected initial marketing authorization applications (iMAAs) and post-authorization applications submitted to the EMA.
Q&A 2022 Annual Report